IP Library Granted Patent US 9,067,882
Granted Patent B2
US 9,067,882 · App. 13/883,487 · Granted Jun 30, 2015

Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,067,882
App. No.
13/883,487
Granted
Jun 30, 2015
Kind
B2
Abstract

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids comprising at least one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

Claims (27)

1. A cationic lipid of Formula A:

wherein:

R 1 is selected from H, and (C 1 -C 6 )alkyl, wherein said alkyl are optionally substituted with one to three substituents selected from R″;

n and m are 1;

X is O;

L 1 is C 12 -C 24 alkenyl, said alkenyl are optionally substituted with one or more substituents selected from R″; and

L 2 is selected from C 3 -C 9 alkyl said alkyl are optionally substituted with one or more substituents selected from R″;

R″ is independently selected from H and (C 1 -C 6 )alkyl;

or any pharmaceutically acceptable salt or stereoisomer thereof.

2. A cationic lipid of Formula A according to claim 1 , wherein:

R 1 is H or methyl;

n and m are 1;

X is O;

L 1 is C 12 -C 24 alkenyl; and

L 2 is C 3 -C 9 alkyl;

or any pharmaceutically acceptable salt or stereoisomer thereof.

3. A cationic lipid which is:

trans-1-Methyl-3-[((9Z,12Z)-octadeca-9,12-dienyl)oxy]-4-octyloxy-pyrrolidine (Compound 4);

trans-1-methyl-3-[(9Z)-octadec-9-en-1-yloxy]-4-(octyloxy)pyrrolidine (Compound 5);

trans-1-methyl-3-[(12Z)-octadec-12-en-1-yloxy]-4-(octyloxy)pyrrolidine (Compound 6);

trans-3-[(3,7-dimethyloctyl)oxy]-1-methyl-4-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]pyrrolidine (Compound 7);

cis-1-methyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-4-(octyloxy)pyrrolidine (Compound 11)

or any pharmaceutically acceptable salt or stereoisomer thereof.

4. A lipid nanoparticle comprising a cationic lipid according to claim 1 .

5. The lipid nanoparticle according to claim 4 further comprises an oligonucleotide.

6. The lipid nanoparticle according to claim 5 wherein the oligonucleotide is siRNA or miRNA.

7. The lipid nanoparticle according to claim 6 wherein the oligonucleotide is siRNA.

Assignments (3)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2014
From: MERCK SHARP & DOHME CORP.
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 032724/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2013
From: STANTON, MATTHEW G.; BEUTNER, GREGORY L.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 031559/0220 →